Filana Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Filana Therapeutics, Inc. carries a market capitalization of 33.20M, placing it among publicly traded companies globally. Its enterprise value stands at -25.19M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 33.20M |
| Enterprise Value | -25.19M |
Share Statistics
Filana Therapeutics, Inc. currently has 48.31M shares outstanding.
| Shares Outstanding | 48.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.90 |
| P/TBV Ratio | 0.90 |
| P/FCF Ratio | -2.04 |
| P/OCF Ratio | -2.00 |
Financial Position
Filana Therapeutics, Inc. maintains a current ratio of 2.08, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.08 |
| Quick Ratio | 2.06 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -55.78 |
| Return on Assets (ROA) | -35.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Filana Therapeutics, Inc.'s stock has declined approximately -66.47317% over the past 52 weeks. The 50-day moving average sits at 0.85, while the 200-day moving average is 1.42.
| Beta (5Y) | N/A |
| 52-Week Price Change | -66.47317% |
| 50-Day Moving Average | 0.85 |
| 200-Day Moving Average | 1.42 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -45.72M, while operating income came in at -46.71M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -46.71M |
| Pretax Income | -42.28M |
| Net Income | -42.28M |
| EBITDA | -45.72M |
| EBIT | -46.71M |
| Earnings Per Share (EPS) | -0.88 |
Balance Sheet
Total book value stands at 63.61M, with working capital of 43.57M providing operational flexibility.
| Cash & Cash Equivalents | 82.68M |
| Total Debt | N/A |
| Net Debt | -82.68M |
| Equity (Book Value) | 63.61M |
| Book Value Per Share | 1.32 |
| Working Capital | 43.57M |
Cash Flow
Filana Therapeutics, Inc. produced -28.70M in operating cash flow over the past twelve months. After subtracting -581,000.00 in capital expenditures, free cash flow totaled -29.28M - equivalent to -0.61 per share.
| Operating Cash Flow | -28.70M |
| Capital Expenditures | -581,000.00 |
| Free Cash Flow | -29.28M |
| FCF Per Share | -0.61 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.69 |
| FCF Yield | -48.92 |
Scores
Filana Therapeutics, Inc. posts an Altman Z-Score of -7.06, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.06 |